Process development and scale-up of PPAR α/γ Dual agonist lobeglitazone sulfate (CKD-501)

Hong Woo Lee, Joong Bok Ahn, Sung Kwon Kang, Soon Kil Ahn, Deok-Chan Ha

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A scaleable synthetic route to the potent PPARα/γ dual agonistic agent, lobeglitazone (1), used for the treatment of type-2 diabetes was developed. The synthetic pathway comprises an effective five-step synthesis. This process involves a consecutive synthesis of the intermediate, pyrimidinyl aminoalcohol (6), from the commercially available 4,6-dichloropyrimidine (3) without the isolation of pyrimidinyl phenoxy ether (4). Significant improvements were also made in the regioselective 1,4-reduction of the intermediate, benzylidene-2,4-thiazolidinedione (10), using Hantzsch dihydropyridine ester (HEH) with silica gel as an acid catalyst. The sulfate salt form of lobeglitazone was selected as a candidate compound for further preclinical and clinical study. More than 2 kg of lobeglitazone sulfate (CKD-S01, 2) was prepared in 98.5% purity after the GMP batch. Overall yield of 2 was improved to 52% from 17% of the original medicinal chemistry route.

Original languageEnglish
Pages (from-to)190-199
Number of pages10
JournalOrganic Process Research and Development
Volume11
Issue number2
DOIs
Publication statusPublished - 2007 Mar 1

Fingerprint

Peroxisome Proliferator-Activated Receptors
Sulfates
sulfates
routes
silica gel
synthesis
esters
ethers
isolation
purity
Pharmaceutical Chemistry
Silica Gel
chemistry
Medical problems
salts
catalysts
Ether
Type 2 Diabetes Mellitus
acids
Esters

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry

Cite this

Process development and scale-up of PPAR α/γ Dual agonist lobeglitazone sulfate (CKD-501). / Lee, Hong Woo; Ahn, Joong Bok; Kang, Sung Kwon; Ahn, Soon Kil; Ha, Deok-Chan.

In: Organic Process Research and Development, Vol. 11, No. 2, 01.03.2007, p. 190-199.

Research output: Contribution to journalArticle

Lee, Hong Woo ; Ahn, Joong Bok ; Kang, Sung Kwon ; Ahn, Soon Kil ; Ha, Deok-Chan. / Process development and scale-up of PPAR α/γ Dual agonist lobeglitazone sulfate (CKD-501). In: Organic Process Research and Development. 2007 ; Vol. 11, No. 2. pp. 190-199.
@article{e0defcc1cf104453a27e969e0d20c030,
title = "Process development and scale-up of PPAR α/γ Dual agonist lobeglitazone sulfate (CKD-501)",
abstract = "A scaleable synthetic route to the potent PPARα/γ dual agonistic agent, lobeglitazone (1), used for the treatment of type-2 diabetes was developed. The synthetic pathway comprises an effective five-step synthesis. This process involves a consecutive synthesis of the intermediate, pyrimidinyl aminoalcohol (6), from the commercially available 4,6-dichloropyrimidine (3) without the isolation of pyrimidinyl phenoxy ether (4). Significant improvements were also made in the regioselective 1,4-reduction of the intermediate, benzylidene-2,4-thiazolidinedione (10), using Hantzsch dihydropyridine ester (HEH) with silica gel as an acid catalyst. The sulfate salt form of lobeglitazone was selected as a candidate compound for further preclinical and clinical study. More than 2 kg of lobeglitazone sulfate (CKD-S01, 2) was prepared in 98.5{\%} purity after the GMP batch. Overall yield of 2 was improved to 52{\%} from 17{\%} of the original medicinal chemistry route.",
author = "Lee, {Hong Woo} and Ahn, {Joong Bok} and Kang, {Sung Kwon} and Ahn, {Soon Kil} and Deok-Chan Ha",
year = "2007",
month = "3",
day = "1",
doi = "10.1021/op060087u",
language = "English",
volume = "11",
pages = "190--199",
journal = "Organic Process Research and Development",
issn = "1083-6160",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Process development and scale-up of PPAR α/γ Dual agonist lobeglitazone sulfate (CKD-501)

AU - Lee, Hong Woo

AU - Ahn, Joong Bok

AU - Kang, Sung Kwon

AU - Ahn, Soon Kil

AU - Ha, Deok-Chan

PY - 2007/3/1

Y1 - 2007/3/1

N2 - A scaleable synthetic route to the potent PPARα/γ dual agonistic agent, lobeglitazone (1), used for the treatment of type-2 diabetes was developed. The synthetic pathway comprises an effective five-step synthesis. This process involves a consecutive synthesis of the intermediate, pyrimidinyl aminoalcohol (6), from the commercially available 4,6-dichloropyrimidine (3) without the isolation of pyrimidinyl phenoxy ether (4). Significant improvements were also made in the regioselective 1,4-reduction of the intermediate, benzylidene-2,4-thiazolidinedione (10), using Hantzsch dihydropyridine ester (HEH) with silica gel as an acid catalyst. The sulfate salt form of lobeglitazone was selected as a candidate compound for further preclinical and clinical study. More than 2 kg of lobeglitazone sulfate (CKD-S01, 2) was prepared in 98.5% purity after the GMP batch. Overall yield of 2 was improved to 52% from 17% of the original medicinal chemistry route.

AB - A scaleable synthetic route to the potent PPARα/γ dual agonistic agent, lobeglitazone (1), used for the treatment of type-2 diabetes was developed. The synthetic pathway comprises an effective five-step synthesis. This process involves a consecutive synthesis of the intermediate, pyrimidinyl aminoalcohol (6), from the commercially available 4,6-dichloropyrimidine (3) without the isolation of pyrimidinyl phenoxy ether (4). Significant improvements were also made in the regioselective 1,4-reduction of the intermediate, benzylidene-2,4-thiazolidinedione (10), using Hantzsch dihydropyridine ester (HEH) with silica gel as an acid catalyst. The sulfate salt form of lobeglitazone was selected as a candidate compound for further preclinical and clinical study. More than 2 kg of lobeglitazone sulfate (CKD-S01, 2) was prepared in 98.5% purity after the GMP batch. Overall yield of 2 was improved to 52% from 17% of the original medicinal chemistry route.

UR - http://www.scopus.com/inward/record.url?scp=34247258462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247258462&partnerID=8YFLogxK

U2 - 10.1021/op060087u

DO - 10.1021/op060087u

M3 - Article

AN - SCOPUS:34247258462

VL - 11

SP - 190

EP - 199

JO - Organic Process Research and Development

JF - Organic Process Research and Development

SN - 1083-6160

IS - 2

ER -